Phase II study of vibegron in women with abdominal pain due to irritable bowel syndrome fails to meet primary endpoint

Achievement of at least 30% improvement in average worst abdominal pain over a 12-week period was seen in 40.9% of those randomised to vibegron, a small molecule beta-3 agonist, compared to 42.9% in the placebo group.

Source:

Biospace Inc.